Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620042166> ?p ?o ?g. }
- W2620042166 endingPage "88452" @default.
- W2620042166 startingPage "88437" @default.
- W2620042166 abstract "The Hippo pathway regulates organ size, growth and comprises several tumor related factors, including the oncoprotein YAP1 and the tumor suppressor RASSF1A. RASSF1A is frequently epigenetically inactivated in cancer. In our study, we analyzed the effect of RASSF1A on the function of YAP1. Expression of YAP1 resulted in the downregulation of several tumor suppressor genes and induction of S-phase. Co-expression with RASSF1A normalized the expression levels of these tumor suppressors and induced a G0-G1 arrest and apoptosis. This effect was associated with the reduction of MDM2 and the increase of p53. These data suggest that the tumor suppressor RASSF1A inhibits the oncogenic potential of YAP1. Additionally, we could show that ANKRD1 is a YAP1 target gene that is induced by RASSF1A. Further analysis revealed that ANKRD1 is epigenetically inactivated in human cancer. ANKRD1 expression induced the expression of TP53 as well as BAX and CDKN1A and reduced colony formation of cancer cells. We found that ANKRD1 interacts with p53 and is involved in the destabilization of MDM2. Additionally, our data indicate that the tumor-suppressive effect of ANKRD1 depends on the presence of p53. These results suggest that ANKRD1 is a tumor-suppressive downstream target of the Hippo pathway that is epigenetically silenced in human cancer." @default.
- W2620042166 created "2017-06-05" @default.
- W2620042166 creator A5023051983 @default.
- W2620042166 creator A5051373487 @default.
- W2620042166 creator A5051977075 @default.
- W2620042166 creator A5053104118 @default.
- W2620042166 creator A5055043533 @default.
- W2620042166 creator A5085769815 @default.
- W2620042166 date "2017-05-23" @default.
- W2620042166 modified "2023-10-16" @default.
- W2620042166 title "The tumor suppressor RASSF1A induces the YAP1 target gene <i>ANKRD1</i> that is epigenetically inactivated in human cancers and inhibits tumor growth" @default.
- W2620042166 cites W1504197144 @default.
- W2620042166 cites W1539804860 @default.
- W2620042166 cites W1929037325 @default.
- W2620042166 cites W1963567108 @default.
- W2620042166 cites W1968659021 @default.
- W2620042166 cites W1968910405 @default.
- W2620042166 cites W1969104713 @default.
- W2620042166 cites W1975284118 @default.
- W2620042166 cites W1977328779 @default.
- W2620042166 cites W1978173004 @default.
- W2620042166 cites W1982030062 @default.
- W2620042166 cites W1986406749 @default.
- W2620042166 cites W1987941191 @default.
- W2620042166 cites W1991961196 @default.
- W2620042166 cites W1992294689 @default.
- W2620042166 cites W1992845452 @default.
- W2620042166 cites W1993320949 @default.
- W2620042166 cites W1993781326 @default.
- W2620042166 cites W1995013322 @default.
- W2620042166 cites W1999490008 @default.
- W2620042166 cites W2003044806 @default.
- W2620042166 cites W2007079916 @default.
- W2620042166 cites W2009597834 @default.
- W2620042166 cites W2011121500 @default.
- W2620042166 cites W2011818472 @default.
- W2620042166 cites W2026242300 @default.
- W2620042166 cites W2027664358 @default.
- W2620042166 cites W2027928327 @default.
- W2620042166 cites W2035150073 @default.
- W2620042166 cites W2036243096 @default.
- W2620042166 cites W2042318470 @default.
- W2620042166 cites W2063110349 @default.
- W2620042166 cites W2064644124 @default.
- W2620042166 cites W2080560721 @default.
- W2620042166 cites W2087766778 @default.
- W2620042166 cites W2099709490 @default.
- W2620042166 cites W2105073325 @default.
- W2620042166 cites W2105193974 @default.
- W2620042166 cites W2105406852 @default.
- W2620042166 cites W2108260772 @default.
- W2620042166 cites W2118055059 @default.
- W2620042166 cites W2123184611 @default.
- W2620042166 cites W2125091346 @default.
- W2620042166 cites W2134479723 @default.
- W2620042166 cites W2134937820 @default.
- W2620042166 cites W2143929604 @default.
- W2620042166 cites W2148056172 @default.
- W2620042166 cites W2149432374 @default.
- W2620042166 cites W2150094472 @default.
- W2620042166 cites W2156440815 @default.
- W2620042166 cites W2157366672 @default.
- W2620042166 cites W2157912474 @default.
- W2620042166 cites W2165767110 @default.
- W2620042166 cites W2167978765 @default.
- W2620042166 cites W2168047241 @default.
- W2620042166 cites W2170494099 @default.
- W2620042166 cites W2171501785 @default.
- W2620042166 cites W2178681339 @default.
- W2620042166 cites W2317570906 @default.
- W2620042166 cites W2525346244 @default.
- W2620042166 doi "https://doi.org/10.18632/oncotarget.18177" @default.
- W2620042166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5687617" @default.
- W2620042166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29179447" @default.
- W2620042166 hasPublicationYear "2017" @default.
- W2620042166 type Work @default.
- W2620042166 sameAs 2620042166 @default.
- W2620042166 citedByCount "28" @default.
- W2620042166 countsByYear W26200421662017 @default.
- W2620042166 countsByYear W26200421662018 @default.
- W2620042166 countsByYear W26200421662019 @default.
- W2620042166 countsByYear W26200421662020 @default.
- W2620042166 countsByYear W26200421662021 @default.
- W2620042166 countsByYear W26200421662022 @default.
- W2620042166 countsByYear W26200421662023 @default.
- W2620042166 crossrefType "journal-article" @default.
- W2620042166 hasAuthorship W2620042166A5023051983 @default.
- W2620042166 hasAuthorship W2620042166A5051373487 @default.
- W2620042166 hasAuthorship W2620042166A5051977075 @default.
- W2620042166 hasAuthorship W2620042166A5053104118 @default.
- W2620042166 hasAuthorship W2620042166A5055043533 @default.
- W2620042166 hasAuthorship W2620042166A5085769815 @default.
- W2620042166 hasBestOaLocation W26200421661 @default.
- W2620042166 hasConcept C104317684 @default.
- W2620042166 hasConcept C121608353 @default.
- W2620042166 hasConcept C127561419 @default.
- W2620042166 hasConcept C172512520 @default.
- W2620042166 hasConcept C179185449 @default.